

CLAIMS

1. A combination of a tumor necrosis factor receptor superfamily (TNFRSF) agonist or a functional fragment thereof and an interferon (IFN) agent or a functional fragment thereof, for use for treating a HBV infection.
2. The combination for its use according to claim 1, wherein the TNFRSF agonist or a functional fragment thereof is selected from the group consisting of a lymphotoxin alpha 3 receptor agonist, a lymphotoxin beta receptor agonist, a herpesvirus entry mediator agonist, a tumor necrosis factor-like receptor weak inducer of apoptosis agonist, a cluster of differentiation factor 40 agonist, a CD27 agonist, a CD30 agonist, a 4-1BB agonist, a receptor activator of nuclear factor κ B agonist, a Troy agonist, and a OX40 receptor agonist, or functional fragments thereof.
3. The combination for its use according to claim 1 or 2, wherein the TNFRSF agonist or a functional fragment thereof is selected from the group consisting of CD40L, LT α 3, LIGHT and TWEAK, or functional fragments thereof.
4. The combination for its use according to any one of claims 1 to 3, wherein the TNFRSF agonist or a functional fragment thereof is selected from the group consisting of CD40L, LIGHT and TWEAK, or functional fragments thereof.
5. The combination for its use according to any one of claims 1 to 4, wherein the TNFRSF agonist or a functional fragment thereof is a CD40 agonist or a functional fragment thereof selected from the group consisting of a CD40 ligand (CD40L) or a functional fragment thereof, an agonistic anti-CD40 antibody, a functional fragment thereof or antigen-binding fragment thereof, and a fusion protein comprising a CD40 ligand or a functional fragment thereof.

6. The combination for its use according to claim 5, wherein the CD40L is hexameric CD40L or trimeric CD40L.

7. The combination for its use according to any one of claims 1 to 6, wherein the
5 TNFRSF agonist or a functional fragment thereof is a polypeptide or a functional fragment thereof, an antibody or a functional fragment thereof, or an antigen-binding fragment thereof.

8. The combination for its use according to any one of claims 1 to 7, wherein the
10 TNFRSF agonist or a functional fragment thereof is provided as a fusion protein comprising said TNFRSF agonist or a functional fragment thereof.

9. The combination for its use according to any one of claims 1 to 8, wherein the
15 IFN agent or a functional fragment thereof is selected from the group consisting of a Type I IFN agent, a Type II IFN agent and a Type III IFN agent, or functional fragments thereof.

10. The combination for its use according to any one of claims 1 to 9, wherein the
IFN agent or a functional fragment thereof is IFN α , IFN β , IFN γ or IFN λ , or functional fragments thereof.

20 11. The combination for its use according to any one of claims 1 to 10, wherein the IFN agent or a functional fragment thereof is IFN β or IFN γ , or functional fragments thereof.

25 12. The combination for its use according to any one of claims 1 to 11, wherein the IFN agent or a functional fragment thereof is IFN β , or a functional fragment thereof.

13. The combination for its use according to any one of claims 1 to 10, wherein the IFN agent or a functional fragment thereof is IFN α , or a functional fragment thereof.

14. The combination for its use according to any one of claims 1 to 13, wherein the IFN agent or a functional fragment thereof is provided as a fusion protein comprising said IFN agent or a functional fragment thereof.

5 15. The combination for its use according to any one of claims 1 to 14, wherein the TNFRSF agonist or a functional fragment thereof and the IFN agent or a functional fragment thereof are provided as a bifunctional immunostimulatory fusion protein comprising the said TNFRSF agonist or a functional fragment thereof, the said IFN agent or a functional fragment thereof and a linker.

10

16. The combination for its use according to any one of claims 1 to 15, wherein the TNFRSF agonist or a functional fragment thereof and the IFN agent or a functional fragment thereof are comprised in a single pharmaceutical composition.

15 17. The combination for its use according to any one of claims 1 to 14, wherein the TNFRSF agonist or a functional fragment thereof and the IFN agent or a functional fragment thereof are comprised in distinct pharmaceutical compositions.

20 18. A pharmaceutical composition comprising:
a TNFRSF agonist or a functional fragment thereof; and
a Type II IFN agent, a functional fragment of a Type II IFN agent, a Type III IFN agent, or a functional fragment of a Type III IFN agent.